Connect Biopharma Holdings (CNTB)

Connect Biopharma Holdings Stock Analysis & Ratings

CNTB Stock Chart & Stats

Day’s Range$0.75 - $0.85
52-Week Range$0.56 - $29.27
Previous Close$0.75
Average Volume (3M)215.48K
Market Cap$44.43M
P/E Ratio-0.2
Next EarningsApr 01, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)-4.16

Connect Biopharma Holdings News

Currently, no data available
Please return soon. This page is being updated.




P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.56 and its highest was $29.27 in the past 12 months.
    What is Connect Biopharma Holdings’s market cap?
    Connect Biopharma Holdings’s market cap is $44.43M.
      What is Connect Biopharma Holdings’s price target?
      The average price target for Connect Biopharma Holdings is $1.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $1.50 ,the lowest forecast is $1.50. The average price target represents 85.94% Increase from the current price of $0.807.
        What do analysts say about Connect Biopharma Holdings?
        Connect Biopharma Holdings’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Connect Biopharma Holdings’s upcoming earnings report date?
          Connect Biopharma Holdings’s upcoming earnings report date is Apr 01, 2022 which is 46 days ago.
            How were Connect Biopharma Holdings’s earnings last quarter?
            Connect Biopharma Holdings released its earnings results on Aug 31, 2021. The company reported -$2.963 earnings per share for the quarter, missing the consensus estimate of -$0.238 by -$2.725.
              Is Connect Biopharma Holdings overvalued?
              According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
                Does Connect Biopharma Holdings pay dividends?
                Connect Biopharma Holdings does not currently pay dividends.
                What is Connect Biopharma Holdings’s EPS estimate?
                Connect Biopharma Holdings’s EPS estimate is -$0.92.
                  How many shares outstanding does Connect Biopharma Holdings have?
                  Connect Biopharma Holdings has 55,080,000 shares outstanding.
                    What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
                    Connect Biopharma Holdings reported an EPS of -$2.963 in its last earnings report, missing expectations of -$0.238. Following the earnings report the stock price went up 0.993%.
                      Which hedge fund is a major shareholder of Connect Biopharma Holdings?
                      Among the largest hedge funds holding Connect Biopharma Holdings’s share is RA Capital Management. It holds Connect Biopharma Holdings’s shares valued at 21M.


                        Connect Biopharma Holdings Stock Analysis

                        Smart Score
                        Price Target
                        ▲(85.94% Upside)
                        Moderate Buy
                        The Connect Biopharma Holdings stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                        Learn more about TipRanks Smart Score

                        Company Description

                        Connect Biopharma Holdings

                        Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.

                        Similar Stocks
                        No data currently available

                        Popular Stocks

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis